Theravance Biopharma, Inc. Unrecognized Tax Benefits, Interest on Income Taxes Expense
Theravance Biopharma, Inc. (TBPH) reported Unrecognized Tax Benefits, Interest on Income Taxes Expense of $5.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties › Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense · last filed 2026-03-23
- Theravance Biopharma, Inc. unrecognized tax benefits, interest on income taxes expense for fiscal 2025 was $5.50M, a 1.79% decline from fiscal 2024.
- Theravance Biopharma, Inc. unrecognized tax benefits, interest on income taxes expense for fiscal 2024 was $5.60M.
| Period end | Unrecognized Tax Benefits, Interest on Income Taxes Expense 12 month |
|---|---|
| 2025-12-31 | $5.50M 10-K · filed 2026-03-23 |
| 2024-12-31 | $5.60M 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |